I enkeltdosis overkrydsningsundersøgelser af Neoclarityn 5 mg smeltetablet over for konventionelle Neoclarityn 5 mg tabletter var formuleringerne bioækvivalente.
In single-dose crossover studies of Neoclarityn 5 mg orodispersible tablets with Neoclarityn 5 mg conventional tablets or Neoclarityn 5 mg oral lyophilisate, the formulations were bioequivalent.